AI-generated analysis. Always verify with the original filing.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an 8-K/A incorporating Item 2.01 disclosures from the Original Report regarding the completion of its acquisition of MindWave Innovations Inc., treated as a reverse acquisition with MindWave as the accounting acquirer. Exhibit 99 provides MindWave's unaudited financials as of September 30, 2025, audited financials as of March 31, 2025, and unaudited pro forma combined financial information.
Event Type
Disclosure
Amendment
Variant
8-K/A
Completion of Acquisition or Disposition of Assets. The disclosure set forth under Item 2.01 in the Company’s Original Report is incorporated herein by referenc
Financial Statements and Exhibits. (a) Financial Statements of Business Acquired ● Unaudited consolidated financial statements as of September 30, 2025, and for
Acquisition / Disposition
Debt / Financing